Fox E, et al. Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS). ECTRIMS 2018, abstract 229.
Verstoorde balans tussen hersennetwerken bij mensen met MS met cognitieve problemen
feb 2017 | Multipele Sclerose